Future hepatitis C virus treatment: Interferon-sparing combinations

Liver International

Volumn 31, Issue SUPPL. 1, 2011, Pages 62-67

  Gane, Edward ^a  

^a New Zealand Liver Transplant Unit   (New Zealand)

Author keywords

Direct acting antiviral (DAA); Hepatitis C; Pegylated interferon; Polymerase inhibitor; Protease inhibitor; Standard of care (SOC)

Indexed keywords

ABT 072; ABT 333; ABT 450; ACH 1625; ALISPORIVIR; ANA 598; AZD 7295; BI 201335; BI 207127; BMS 650032; BMS 790052; BMS 791325; BMS 824393; BOCEPREVIR; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; DANOPREVIR; GS 9190; GS 9256; IDX 184; IDX 320; IDX 375; INTERFERON; MK 0608; MK 3281; N [[[6 (2 CARBOXY 2,3 DIHYDRO 1H ISOINDOL 4 YL) 2,2 DIMETHYLHEXYL]OXY]CARBONYL] 3 METHYLVALYL 4 HYDROXYPROLYL 1 AMINO N (CYCLOPROPYLSULFONYL) 2 ETHYLCYCLOPROPANECARBOXAMIDE LACTONE; NARLAPREVIR; PEGINTERFERON; PPI 1301; PPI 461; PROTEINASE INHIBITOR; PSI 7977; RG 7128; RG 7348; RIBAVIRIN; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 222; VX 759; VX 985;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; TREATMENT DURATION;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; PROTEASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRUS REPLICATION;

EID: 78650806908     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02383.x     Document Type: Article

References (32)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl. 1): 74-81.
2. CDC Compressed Mortality File. Available at (accessed 1 June 2008).
3. National Health and Nutrition Examination Surveys 1988-2006. Available at (accessed 1 June 2008).
4. Armstrong G, Wasley A, Simard E, et al. Prevalence of HCV infection in the United States. Ann Int Med 2006; 144: 705-14.
5. Wise M, Bialek S, Bell B, et al. Changing trends in HCV-related mortality in USA. Hepatology 2008; 47: 1128-35.
6. Davila J, Morgan R, Shaib Y, et al. HCV and increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-80.
7. Davis G, Albright J, Cook S. Projecting future complications of chronic hepatitis C in United States. Gastroenterology 2010; 139: 331-8.
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
10. Ge D, Fellay J, Thompson A, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
11. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
12. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
13. Thompson A, Muir A, Sulkowski M, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-29.
14. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-8.
15. Jacobson I, McHutchison J, Dusheiko G, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of phase 3 ADVANCE study. Hepatology 2010; 52: 427A.
16. Poordad F, McCone J, Bacon B, et al. Boceprevir (BOC) combined with Peginterferon alfa-2b/ribavirin (P/R) for Treatment-naïve patients with hepatitis C Virus (HCV) genotype (G) 1: SPRINT-2 final Results. Hepatology 2010; 52: 402A.
17. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
18. Berg T, McHutchison N. Adda, SVR with telaprevir, peginterferon alfa-2a and ribavirin in HCV patients with well-characterized prior null response, partial response, viral breakthrough or relapse after PR: rollover study 107. J Hepatol 2010; 52: S2.
19. Bruce R, Bacon B, Gordon S, et al. HCV RESPOND-2 final results: high sustained virologic response among Genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with Boceprevir plus pegintron (peginterferon alfa- 2b)/ribavirin. Hepatology 2010; 52: 430A.
20. Asselah T, Benhamou Y, Marcellin P. Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int 2009; 29 (Suppl. 1): 57-67.
21. Foster G, Hézode C, Bronowicki JP, et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve, genotype 2 and 3, hepatitis C patients: Final Results of Study C209. J Hepatol 2010; 52: S27.
22. Tan H, Rajyaguru S, Wu T, et al. Combination of NS3/4a protease inhibitor ITMN-191 (R7227) with the active moiety of the NS5b inhibitors R1626 or R7128 enhances viral clearance and reduces emergence of drug-resistant variants. Hepatology 2008; 48: 1153A.
23. Koev G, Dekhtyar T, Han L, et al. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antiviral Res 2007; 73: 78-83.
24. Zennou V, Lam A, Keilman M, et al. Combination of two complementary mucleotide analogues PSI7977 and PSI938 effectively clears wild type and NS5b-S282T HCV replicons. J Hepatol 2010; 52: S400.
25. Olsen DB, Carroll SS, Handt L, et al. HCV antiviral activity andresistance analysis in chronically infected chimpanzees treated with NS3/4A protease and NS513 polymerase inhibitors. J Hepatol 2007; 46: S298.
26. Gane E, Roberts S, Stedman C, et al. Interferon-free oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and protease inhibitor (danoprevir/RG7227) for the treatment of chronic hepatitis C genotype 1 infection: results of the INFORM-1 trial. Lancet 2010; 376: 1467-75.
27. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-8.
28. Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44: 1617-25.
29. Shulman N, Smith P, Ipe D, et al. Reduction of IP10, a biomarker of endogenous IFN, during therapy with two direct-acting antiviral agents (DAA-combo) in INFORM-1 suggests that reducing HCV RNA with IFN-free therapy may enhance response to Interferons. 16th International Symposium on HCV and Related Viruses, October 3-7 2009, Nice, France.
30. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 516-24.
31. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistant mutations to HCV protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-78.
32. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 183-50.